Pulmonary Hypertension
An Introduction to Pulmonary Hypertension
With advancements in pulmonary hypertension (PH) pathobiology over the past 20 years, more than a dozen therapies are available for the treatment of pulmonary arterial hypertension and chronic thromboembolic PH. Efforts have focused on identifying novel pathogenic targets towards the development efficacious, disease-modifying therapies. There is currently a surge in the development of novel agents, including those to rebalance bone morphogenetic protein receptor type II (BMPR-II) signalling, stimulate soluble guanylate cyclase and inhibit the nuclear factor-kappa B (NF-κB) pathway.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape
Our supporting partners do not constitute an endorsement of the content on this page.
What were the key advances in pulmonary arterial hypertension at ATS 2026? In this interview, Dr Namita Sood shares her personal highlights from the meeting, discusses the importance of incorporating the patient perspective into care and research, and reflects on emerging treatments and evolving approaches to PAH assessment and management.
The American Thoracic Society’s annual conference was held in Orlando, Florida from May 15-20, bringing together global experts in pulmonary, critical care, and sleep medicine. Across the week, attendees shared new research and clinical advances through scientific sessions, abstract presentations, and collaborative discussions aimed at improving respiratory care and patient outcomes. In this interview, Dr Jean Elwing (University of Cincinnati, Cincinnati, OH, USA) breaks down the key presentations, sessions and abstracts from the conference, highlighting the substantial progress made in the field and the challenges that still remain
Innovation in pulmonary hypertension does not happen in isolation. It requires coordinated global effort, cross-sector collaboration, and a willingness to confront long-standing clinical challenges with fresh thinking. That is precisely the ambition behind the Innovative Drug Discovery Initiative (IDDI) Workstreams, a flagship initiative of the Pulmonary Vascular Research Institute (PVRI).
The PVRI 2026 Congress in Dublin marked not only the return of a global gathering of pulmonary vascular specialists, but also a significant milestone—the 20th anniversary of the Pulmonary Vascular Research Institute (PVRI). Under the theme “Celebrating 20 Years of Progress & Innovation,” the meeting offered an opportunity to reflect on 2 decades of scientific advancements, while looking ahead to the future of pulmonary vascular research and care.
The CHEST 2025 annual meeting brought together pulmonary, critical care, and sleep medicine experts to share emerging science, clinical insights, and forward-looking innovations shaping respiratory care. Through focused conversations with leaders across the field, these interviews highlight practical, practice-ready insights that clinicians can bring directly to patient care.
CHEST 2025 delivered a dynamic, multidisciplinary program showcasing advances in pulmonary, critical-care, and thoracic medicine. Dr Jean Elwing highlights the most impactful PH-focused sessions, including immersive hemodynamic and imaging training, discussions on integrating sotatercept into PAH care, efforts to address disparities in PH care, and key updates at the intersection of transplant medicine and pulmonary hypertension.
The 2025 PHPN Symposium brought together leading experts in pulmonary hypertension to share cutting-edge research, clinical updates, and emerging therapies. In this Q&A, Dr Jean Elwing highlights standout sessions, including new right heart echocardiography guidelines, health equity challenges, and promising treatments like sotatercept, offering insights into the future of PH care and the ongoing push toward earlier diagnosis and better outcomes.
It is my great pleasure to introduce touchREVIEWS in Respiratory & Pulmonary Diseases, Volume 10, Issue 1, 2025. This issue brings together a collection of timely and thought-provoking articles addressing key challenges and emerging innovations across the spectrum of respiratory and pulmonary care. ...
According to the Seventh World Symposium on Pulmonary Hypertension in 2024, pulmonary hypertension (PH) is defined as a mean pulmonary artery pressure (mPAP) of >20 mmHg. Pre-capillary PH is defined by mPAP of >20 mmHg and elevation of pulmonary vascular resistance (...
July saw important advances in respiratory medicine, including new drug approvals and promising clinical trial results. Notable progress was made in treatments for lung cancer, cystic fibrosis, and pulmonary arterial hypertension, reflecting ongoing efforts to address challenging respiratory conditions. These developments highlight a dynamic period of innovation with the potential to improve patient outcomes and expand therapeutic options.
As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!
Explore expert perspectives from ATS 2025 with our exclusive interview series. Discover key advances in respiratory care, including updates on COPD, ILD, ventilation strategies, and emerging therapies. Stay informed with concise, clinically relevant insights tailored for healthcare professionals on touchRESPIRATORY.
RT234 is a novel investigational therapy combining inhaled dry powder vardenafil with a proprietary oscillating inhaler, designed for rapid, on-demand relief of breathlessness in patients with pulmonary arterial hypertension (PAH). In a phase 2b CPET study, RT234 demonstrated dose-dependent improvements in peak VO₂ and dyspnea.
As part of our ATS 2025 coverage, Dr Raymond Benza discusses these findings, current treatment limitations, and the next steps toward a phase III clinical trial.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
